Madrigal Pharmaceuticals (MDGL) Net Equity Issued and Repurchased (2010 - 2025)

Madrigal Pharmaceuticals (MDGL) has 12 years of Net Equity Issued and Repurchased data on file, last reported at $9.9 million in Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 43313.04% year-over-year to $9.9 million in Q4 2025; TTM through Dec 2025 was $38.1 million, a 90.43% decrease from a year earlier, with the FY2025 full-year figure at $38.1 million, down 90.43% from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at $9.9 million, down from $28.1 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for MDGL reached as high as $262.1 million in Q1 2024 and fell as low as -$23000.0 in Q4 2024.
• Historically, Net Equity Issued and Repurchased has averaged $77.3 million across 3 years, with a median of $28.1 million in 2025.
• Across the five-year window, Net Equity Issued and Repurchased slumped 100.01% in 2024 and jumped 43313.04% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $234.1 million in 2023, then slumped by 100.01% to -$23000.0 in 2024, then soared by 43313.04% to $9.9 million in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $9.9 million in Q4 2025, $28.1 million in Q3 2025, and -$23000.0 in Q4 2024.